As the results shown, in B16F10 melanoma model, Sunitinib alone significantly decreased tumor growth at day 12 after treatment compared to control group (mean tumor size: 1885 vs 2602 mm3; p < 0.001), while a combinatorial treatment of Sunitinib and anti‐CTLA‐4 reach the better efficacy (mean tumor size: 274 vs 2602 mm3; p < 0.001; Figure6A–D). This evidence concerns the gene CTLA4 and neoplasm.